Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lotus OTCs boost retail sales

This article was originally published in The Tan Sheet

Executive Summary

Increased distribution to OTC drug outlets in Beijing helps Lotus Pharmaceuticals grow net retail revenue 52.2 percent to $3.3 million in the Chinese firm's fiscal 2010 first quarter. OTC drugs are a new venture for Lotus, which expects to expand the business with a recently recruited sales team and a storage and distribution facility under construction, the company said May 14. Overall net revenues, largely generated by Lotus' wholesale Rx segment, increased 26.4 percent to $14.9 million in the first quarter 2010. Net income rose 36.1 percent to $4.9 million

You may also be interested in...



Lotus expands OTC business

The Beijing-based pharma says it signed OTC drug purchase agreements with 11 manufacturers during its second quarter, when retail revenues grew 123 percent to $6.2 million, thanks largely to OTC direct sales to Beijing outlets. Lotus Pharmaceuticals only recently entered the OTC business with a new sales team and an under-construction distribution facility (1"The Tan Sheet" May 24, 2010, In Brief). The firm said Aug. 16 its overall net revenue climbed 19.4 percent to $12.7 million in the April-June period and 23.6 percent to $24.2 million in the half

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.

 

 

Topics

UsernamePublicRestriction

Register

PS104139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel